Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules

Lancet

Volumn 354, Issue 9190, 1999, Pages 1598-1603

  Moins Teisserenc, Hélènet ^a,g   Gadola, Stephan D ^a   Cella, Marina ^f   Dunbar, P Rod ^a   Exley, Andrew ^f   Blake, Neil ^b   Baycal, Can ^c   Lambert, Julien ^e   Bigliardi, Paul ^f   Willemsen, Maria ^f   Jones, Margaret ^d   Buechner, Stanislaw ^f   Colonna, Marco ^f   Gross, Wolfgang L ^f   Cerundolo, Vincenzo ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c Department of Dermatology   (Turkey)

^d Division of Cellular Sciences   (United Kingdom)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f Department of Dermatology ^*

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENE LOCUS; GENE MUTATION; GENETIC DISORDER; GRANULOMATOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MALE; NATURAL KILLER CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECESSIVE INHERITANCE; RESPIRATORY TRACT INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN DEFECT; T LYMPHOCYTE; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0033530372     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)04206-3     Document Type: Article

References (21)

1. Gross WL. Wegener's granulomatosis. In: Madison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford textbook of rheumatology. Oxford: Oxford University Press, 1998; 2: 1331-51.
2. Leavitt R.Y., Fauci A.S., Bloch D.A.et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 33:1990;1101-1107.
3. Jennette J.C., Falk R.J., Andrassy K.et al. Nomenclature of systemic vasculitides. Arthritis Rheum. 37:1994;187-192.
4. Russ G., Esquivel F., Yewdell J.W.et al. Assembly, intracellular localization, and nucleotide binding properties of the human peptide transporters TAP1 and TAP2 expressed by recombinant vaccinia viruses. J Biol Chem. 270:1995;21312-21318.
5. Cella M., Longo A., Ferrara G.B., Strominger J.L., Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 180:1994;1235-1242.
6. Fauci A.S., Haynes B.F., Kath P., Wolff S. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 98:1983;76-85.
7. Willemsen D., De Conick A., Goossens A.et al. Unusual clinical manifestations of a disfiguring necrobiotic granulomatous disease. Am Acad Dermatol. 33:1995;887-890.
8. de la Salle H., Zimmer J., Fricker D.et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest. 103:1999;R9-13.
9. Plebani A., Monafo V., Cattaneo R.et al. Defective expressionof HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. J Am Acad Dermatol. 35:1996;814-828.
10. Teisserenc H., Schmit W., Blake N.et al. A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett. 57:1997;183-187.
11. Spies T., Cerundolo V., Colonna M.et al. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature. 355:1992;644-646.
12. Colonna M. Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Immunol Rev. 155:1997;127-133.
13. Lanier L.L., Phillips J.H. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today. 17:1996;86-91.
14. de la Salle H., Hanau D., Fricker D.et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science. 265:1994;237-241.
15. Watanabe S., Iwata M., Maeda H., Ishibashi Y. Immunohistochemical studies of major histocompatibility antigens in a case of the bare lymphocyte syndrome without immunodeficiency. J Am Acad Dermatol. 17:1987;895-902.
16. Furukawa H., Murata S., Yabe T.et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest. 103:1999;755-758.
17. Orange J.S., Biron C.A. Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol. 156:1996;4746-4756.
18. Takashima T., Ohnishi K., Tsuyuguchi I., Kishimoto S. Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN-gamma and IL-4. J Immunol. 150:1993;3002-3010.
19. Zimmer J., Donato L., Hanau D.et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type 1 bare lymphocyte syndrome). J Exp Med. 187:1998;117-122.
20. Zimmer J., Donato L., Hanau D.et al. Inefficient protection of human TAP-deficient fibroblasts from antologous NK cell-mediated lysis by cytokines inducing HLA class I expression. Eur J Immunol. 29:1999;1286-1291.
21. Furukawa H., Yabe T., Watanabe K.et al. Tolerance of NK and LAK activity for HLA class I deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type 1). Hum Immunol. 60:1999;32-40.